Recent legislation establishing a $2,000 out-of-pocket cap in Medicare Part D has the potential to lower out-of-pocket costs for more than 125,000 Part D beneficiaries who use ultra-expensive drugs and are ineligible for low-income subsidies, according to a new JAMA Health Forum analysis.